Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma has presented new Phase 2a clinical trial data at the EASL Congress, demonstrating that their drug imdusiran, in combination with interferon and ongoing therapy, effectively reduced HBsAg levels, with some patients maintaining undetectable levels post-treatment, indicating a potential functional cure for chronic hepatitis B. The treatment was safe and well-tolerated, with no serious adverse events, supporting the possibility of a functional cure for the millions affected by HBV globally.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
